Here is everything from Harrison's Section 1 Pain - Chapter 14: Pain: Pathophysiology and Management (22nd Edition, 2025):
Harrison's Section 1: Pain (Chapter 14)
Authors: James P. Rathmell, Howard L. Fields
Overview
Pain is the most common symptom bringing patients to a physician. The pain sensory system functions to protect the body by detecting, localizing, and identifying potential or actual tissue-damaging processes. Pain has a dual nature - it is both a sensation and an emotion. Acute pain causes behavioral arousal, stress response (raised BP, HR, pupil diameter, cortisol), and local muscle contraction.
1. THE PAIN SENSORY SYSTEM
Peripheral Mechanisms
Primary Afferent Fibers - Three Types:
| Fiber Type | Diameter | Myelination | Normal Function |
|---|
| A-beta (Aβ) | Large | Heavily myelinated | Light touch / moving stimuli - does NOT produce pain normally |
| A-delta (Aδ) | Small | Thinly myelinated | Pain (fast, sharp, first pain) |
| C fibers | Smallest | Unmyelinated | Pain (slow, burning, second pain) |
- Aδ and C fibers are called primary afferent nociceptors
- Conduction block of Aδ and C fibers completely abolishes detection of painful stimuli
- Nociceptors respond to: heat, intense cold, intense mechanical distortion, acidic pH, ATP, serotonin, bradykinin, histamine
- TRPV1 (vanilloid receptor) - transient receptor potential cation channel; activated by heat, acid pH, capsaicin, and endogenous mediators
Sensitization
When tissue is damaged or inflamed, inflammatory mediators are released that sensitize nociceptors:
- Products of inflammation: bradykinin, prostaglandins, leukotrienes, serotonin, substance P, histamine, H+ ions, ATP, products of proteolysis
- This creates peripheral sensitization - a lowered threshold and increased responsiveness
- Allodynia: pain in response to a normally non-painful stimulus (e.g., sunburned skin painful to light touch)
- Hyperalgesia: exaggerated pain to a normally painful stimulus
Central Mechanisms
Dorsal Horn Processing:
- Aδ and C fibers synapse on neurons in the dorsal horn of the spinal cord
- Glutamate and substance P are the key nociceptive neurotransmitters at these synapses
- Dorsal horn neurons send signals via the spinothalamic tract to the thalamus and cortex
Central Sensitization (Wind-up):
- Repeated C fiber stimulation causes progressive amplification of dorsal horn neuron activity
- Mediated by the NMDA receptor (N-methyl-D-aspartate)
- Wind-up = the progressive increase in dorsal horn neuron firing with repeated stimulation
- Central sensitization contributes to: allodynia, hyperalgesia, and spread of pain beyond the injury site
The Thalamus and Cortex:
- Thalamic relay neurons project to somatosensory cortex (location and quality of pain) and limbic structures (emotional component)
- The anterior cingulate cortex is particularly involved in the suffering/emotional aspect of pain
2. PAIN MODULATION
Endogenous Analgesia Systems
The brain has built-in pain-suppression systems. Key discovery: electrical stimulation of the periaqueductal gray (PAG) produces profound analgesia.
Descending Pain Modulation Pathway:
- PAG → rostral ventromedial medulla (RVM), including the nucleus raphe magnus
- RVM → dorsal horn via the dorsolateral funiculus
- Inhibition of dorsal horn nociceptive neurons
Key Neurotransmitters of Endogenous Analgesia:
- Endorphins, enkephalins, dynorphins - endogenous opioids acting at mu, delta, kappa receptors
- Serotonin (from raphe nuclei)
- Norepinephrine (from locus coeruleus and lateral tegmental noradrenergic neurons)
- Both serotonin and norepinephrine inhibit pain transmission in the dorsal horn - this is the basis for TCA and SNRI analgesia
Opioid Receptors:
- Three main types: mu (μ), delta (δ), kappa (κ)
- Most analgesic opioids act primarily at mu receptors
- Located in brain, spinal cord, and peripheral tissues
The Placebo Effect:
- Placebo analgesia is real and mediated by endogenous opioids - it is reversible by naloxone
- Expectation, conditioning, and context powerfully modulate pain perception
3. NEUROPATHIC PAIN
Neuropathic pain arises from injury or dysfunction of the peripheral or central nervous system (unlike nociceptive pain which arises from tissue damage with intact nerves).
Mechanisms:
- Ectopic discharge: damaged nerves fire spontaneously without a stimulus
- Sympathetically maintained pain: norepinephrine from sympathetic neurons activates nociceptors (contributes to complex regional pain syndrome - CRPS)
- Central sensitization: abnormal amplification in the dorsal horn and higher centers
- Loss of inhibitory interneurons: reduced GABAergic inhibition in the dorsal horn
Clinical Features of Neuropathic Pain:
- Burning, shooting, electric-shock quality
- Allodynia (pain from light touch)
- Hyperalgesia
- Dysesthesias (unpleasant abnormal sensations)
- Spontaneous pain without ongoing tissue damage
Examples: diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, phantom limb pain, complex regional pain syndrome (CRPS), central poststroke pain
4. ACUTE PAIN MANAGEMENT
Opioid Analgesics
- Mechanism: act at mu receptors in brain, spinal cord, and periphery
- Supraspinal sites: PAG, RVM (activates descending inhibition)
- Spinal sites: direct inhibition of dorsal horn nociceptive neurons
- Peripheral sites: activated in inflamed tissue
Key Points:
- Opioids are the most effective analgesics for moderate-to-severe acute pain
- Tolerance (need higher dose for same effect) and physical dependence (withdrawal on abrupt cessation) are predictable physiologic phenomena - different from addiction
- Addiction = compulsive use despite harm - rare when opioids used appropriately for pain
Common Opioids:
- Morphine - gold standard
- Hydromorphone - more potent, useful in renal failure
- Oxycodone - oral
- Fentanyl - high potency, rapid onset, used IV/transdermal
- Meperidine (pethidine) - avoid for chronic use (normeperidine accumulation causes CNS excitation, seizures)
Side Effects of Opioids:
- Constipation (no tolerance develops - always treat prophylactically)
- Nausea/vomiting
- Sedation, respiratory depression (serious - monitor in opioid-naive)
- Pruritus (especially neuraxial opioids)
- Urinary retention
- Tolerance and physical dependence
NSAIDs and Acetaminophen
- NSAIDs block prostaglandin synthesis (COX inhibition), reducing peripheral sensitization
- Most effective for pain with an inflammatory component
- GI toxicity (COX-1 inhibition) - use PPI prophylaxis
- Selective COX-2 inhibitors (celecoxib): less GI toxicity but cardiovascular risk
- Acetaminophen: effective analgesic/antipyretic; mechanism not fully understood; hepatotoxic in overdose
Adjuvants for Acute Pain
- Ketamine (NMDA antagonist): low-dose IV reduces opioid requirements post-op
- Glucocorticoids: reduce inflammatory pain; also act centrally
- Alpha-2 agonists (clonidine, dexmedetomidine): supraspinal and spinal analgesia
5. CHRONIC PAIN
Definition and Concepts
- Pain persisting beyond normal tissue healing time (conventionally >3 months)
- Biopsychosocial model is essential: biological, psychological, and social factors all contribute
- "Pain behaviors": learned behaviors that persist even after healing
- Emotional distress and depression commonly co-exist and amplify pain perception
- Catastrophizing (fear, helplessness about pain) strongly predicts disability
Assessment
A thorough evaluation should:
- Identify any treatable underlying cause
- Set realistic, functional treatment goals (e.g., sleep better, return to work)
- Quantify impact on function, mood, sleep, and social relationships
- Screen for psychological comorbidities (depression, anxiety, PTSD, substance use)
6. TREATMENT OF CHRONIC PAIN
A. Antidepressant Medications
Tricyclic Antidepressants (TCAs) - First-Line for Many Neuropathic Pains:
- Best choices: nortriptyline and desipramine (better side effect profiles than amitriptyline)
- Analgesia occurs at lower doses and faster than antidepressant effect
- Effective even in non-depressed patients
- Mechanism: block reuptake of serotonin and norepinephrine → enhance descending inhibition
- May potentiate opioid analgesia - useful add-on for cancer pain
Painful Conditions Responding to TCAs (Table 14-2):
- Postherpetic neuralgia
- Diabetic neuropathy
- Fibromyalgia
- Tension headache
- Migraine headache
- Rheumatoid arthritis (benefit but not direct analgesia in controlled studies)
- Chronic low back pain
- Cancer pain
- Central poststroke pain
TCA Side Effects (especially problematic in elderly):
- Orthostatic hypotension
- Drowsiness
- Cardiac conduction delay
- Memory impairment
- Constipation
- Urinary retention
SNRIs (Duloxetine, Venlafaxine):
- Similar mechanism to TCAs but fewer side effects
- Duloxetine FDA-approved for diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain
- Generally preferred over TCAs in older patients
SSRIs:
- Weaker analgesic effect than TCAs or SNRIs
- Useful primarily if depression is the main driver
B. Anticonvulsants / Membrane-Stabilizing Drugs (Table 14-3 region)
Gabapentinoids:
- Gabapentin and pregabalin - bind to α2δ subunit of voltage-gated calcium channels
- Reduce calcium-dependent neurotransmitter release from nociceptive neurons
- First-line for: postherpetic neuralgia, diabetic neuropathy, fibromyalgia (pregabalin)
- Side effects: sedation, dizziness, peripheral edema, weight gain
Carbamazepine:
- First-line for trigeminal neuralgia - blocks sodium channels
- Also used in other lancinating neuropathic pains
- Requires monitoring: CBC, LFTs; risk of aplastic anemia, Stevens-Johnson syndrome (especially in Han Chinese - HLA-B*1502 testing)
Lamotrigine, Oxcarbazepine: alternatives for trigeminal neuralgia
C. Opioids in Chronic Non-Cancer Pain
Chronic opioid therapy (COT) is controversial and must be approached carefully.
CDC Guidelines for Chronic Opioid Therapy (Table 14-3) - Key Principles:
- Use opioids only when benefits outweigh risks; try non-opioid therapies first
- Start low, go slow
- Prescribe the lowest effective dose
- Avoid concurrent benzodiazepines if possible (greatly increases overdose risk)
- Use urine drug testing before and during therapy
- Check prescription drug monitoring programs (PDMPs)
- Use written opioid treatment agreements
- Reassess regularly; taper if risks outweigh benefits
- For patients on ≥50 MME/day - consider risk-benefit; ≥90 MME/day should be carefully justified
- Prescribe naloxone to high-risk patients
- Screen for opioid use disorder (OUD) - if present, offer medication-assisted treatment (buprenorphine, methadone)
Risk Factors for Opioid Misuse:
- Personal or family history of substance use disorder
- Young age
- Depression, anxiety, PTSD
- History of sexual abuse
D. Interventional Procedures
Reserved for patients unresponsive to pharmacologic treatments:
- Epidural glucocorticoid injections: acute radicular pain (e.g., disc herniation)
- Radiofrequency ablation of facet joints: chronic facet-related neck/back pain
- Nerve blocks: diagnostic and therapeutic
- Spinal cord stimulation (SCS): electrodes placed in epidural space over dorsal columns; significant benefit in refractory pain; used for failed back surgery syndrome, CRPS
- Peripheral nerve stimulation
- All invasive procedures should be preceded by multidisciplinary pain clinic evaluation
E. Non-Pharmacologic Approaches
- Physical therapy: essential; improves function, reduces fear-avoidance
- Cognitive-behavioral therapy (CBT): most evidence-based psychological treatment for chronic pain; addresses catastrophizing, pain behaviors, activity avoidance
- Multidisciplinary pain programs: combine medical, psychological, physical rehabilitation
- Mindfulness-based stress reduction (MBSR)
- Acupuncture: modest evidence for some conditions
7. TREATMENT OF NEUROPATHIC PAIN (Summary Algorithm)
First-line agents:
- TCAs (nortriptyline/desipramine) or SNRIs (duloxetine/venlafaxine)
- Gabapentin or pregabalin
- Topical lidocaine patch (for postherpetic neuralgia, localized pain)
- Topical capsaicin (high-concentration patch - 8%)
Second-line:
- Opioids (tramadol first, then stronger opioids)
- Combination therapy
Special cases:
- Trigeminal neuralgia → carbamazepine first-line
- CRPS → early mobilization, sympathetic nerve blocks, SCS
8. KEY TABLES
Table 14-1: Anticonvulsant and TCA Drugs for Neuropathic Pain
Includes: nortriptyline, desipramine, gabapentin, pregabalin, carbamazepine, lamotrigine, topiramate - with doses and side effects
Table 14-2: Painful Conditions Responding to Tricyclics
(listed above)
Table 14-3: CDC Guidelines for Chronic Opioid Therapy
Key: lowest dose, avoid benzodiazepines, urine screening, PDMPs, naloxone prescribing
9. CORE CONCEPTS TO REMEMBER
| Concept | Key Point |
|---|
| First pain | Sharp, fast - carried by Aδ fibers |
| Second pain | Slow, burning - carried by C fibers |
| Allodynia | Pain from non-painful stimulus |
| Hyperalgesia | Exaggerated pain from painful stimulus |
| Wind-up | Central sensitization via NMDA receptors |
| Endogenous analgesia | PAG → RVM → dorsal horn via serotonin/NE |
| Placebo | Real, opioid-mediated (blocked by naloxone) |
| Best TCA choice | Nortriptyline / Desipramine (not amitriptyline) |
| Trigeminal neuralgia | Carbamazepine first-line |
| Avoid in chronic pain | Meperidine (normeperidine toxicity) |
| Opioid + benzo | Avoid - synergistic respiratory depression |
| COX-2 selective | Less GI toxicity but cardiovascular risk |
Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter 14 - Rathmell & Fields, p. 141-146